by heshamhamed | Feb 23, 2024 | News
Adoram management presented before an expert panel for the stage I venture kick startup competition. The concept of Leveraging allosteric biochemistry for patients was found convincing by the jury and was granted 10K CHF. For further details, please refer to the...
by heshamhamed | Feb 23, 2024 | News
We are heading to Sachs’ 16th Annual European Life Sciences CEO forum to discuss the latest data package generated by Adoram Therapeutics. Not only do we show superior efficacy, but more importantly improved safety compared to competitors thanks to our unique MoA....
by heshamhamed | Feb 23, 2024 | News
First day in BioEurope and everyone can already feel the enthusiasm about the market not only stabilizing but showing strong recovery trends. If you are around, let’s have a chat over a coffee. Alot of developments took place over the last year for Adoram...
by heshamhamed | Nov 1, 2022 | News
One or more representatives from Adoram Therapeutics will be attending the events listed below. Please feel free reach out via the contact form, email, or linkedin, if you would like to organize a meeting there. November: Swiss Oncology and Hematology...
by heshamhamed | Oct 13, 2022 | News
Co-founders David Pejoski and Hesham Hamed will attend one of the premier biotech partnering events in Europe, the autumn edition of BioEurope, to be held in Leipzig Germany between the 24th and 26th October 2022. This networking event brings together young biotech...
by heshamhamed | Aug 11, 2022 | News
Adoram Therapeutics has recently been accepted into the Swiss Biotech Association. Our Swiss Biotech company page and Venture Platform listing (for business partnering and investor interactions) can found here Adoram Therapeutics SA...
